|
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of patients with cancer, receives the Issue Notification for patent JP 7232845 titled ‘Methods For Producing (6S,15S)-3,8,13,18- Tetraazaicosane-6,15-DIOL’. This patent is developed in collaboration with Bengaluru-based Syngene.
The process patent claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid till 2039.
Jennifer K Simpson, president & chief executive officer, Panbela Therapeutics, said, “We’re excited to receive the issuance of this patent in Japan. Expansion of our patent portfolio further supports our global clinical programmes.
First issued in the United States, this patent covers a shorter synthesis of SBP-101, which provides many benefits including: the ability to manufacture product with a reduced lead time. There is quicker access to drug supply facilitating expansion into additional indications and enables a scalable, efficient and cost-effective manufacturing process for future commercialization. This patent is the outcome of the dedicated efforts of our valued long-term partner Syngene International in helping us achieve this important goal,” she added.
Jonathan Hunt, managing director and chief executive officer, Syngene International, said, "We have been partnering with Panbela for the last decade, and we laud the work achieved through the successful collaboration. In this case, reducing the number of steps in production from seventeen to six, thus simplifying the manufacturing process and making future commercialization faster, means that the drug will reach patients more quickly. The issuance of a patent in the US in 2021 and now in Japan for SBP-101 are significant milestones.”
“The company expects to continue innovation and patent portfolio building to support our clinical programmes. This process in this patent utilizes a pharmaceutical starting material that is widely available, assuring the company of drug supply moving forward,” Dr. Simpson added.
|